App-Quantinova.ai

HUMAN ERYTHROID PROGENITORS ARE DIRECTLY INFECTED BY SARS-COV-2: IMPLICATIONS FOR EMERGING ERYTHROPOIESIS IN SEVERE COVID19 PATIENTS

Hector Huerga Encabo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

OUTCOMES OF CHILDREN AGED UNDER 3 YEARS TREATED WITH TISAGENLECLEUCEL FOR B-ALL

Sara Ghorashian - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

tisagenlecleucel-t

BASELINE CT THORAX AND RISK OF INVASIVE FUNGAL DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION

Varun Mehra - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Allopurinol

REAL WORLD TWO-CENTER EXPERIENCE OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/ REFRACTORY MULTIPLE MYELOMA

Irene Sanchez - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

daratumumab Intravenous

MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PRIMARY CNS LYMPHOMA: RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS

Gerald Illerhaus - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Methotrexate

IMPACT OF OLIPUDASE ALFA ENZYME REPLACEMENT THERAPY ON PULMONARY, VISCERAL AND HEMATOLOGIC MANIFESTATIONS OF ACID SPHINGOMYELINASE DEFICIENCY: 1-YEAR RESULTS OF CLINICAL TRIALS IN CHILDREN AND ADULTS

Maurizio Scarpa - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Niemann-Pick disease type A

N/A

DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS

Philippe Moreau - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

DISEASE AND OUTCOME ASSOCIATED IMMUNE SIGNATURES AT DIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Edward Truelove - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

GLOFITAMAB STEP-UP DOSING (SUD): UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS)

Carmelo Carlo-Stella - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Obinutuzumab

BCX9930, AN ORAL FACTOR D INHIBITOR, CONTROLS EXTRAVASCULAR HEMOLYSIS AND ALLEVIATES ASSOCIATED SYMPTOMS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

Austin Kulasekararaj - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

N/A

A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ADVANCED MYELOFIBROSIS

Harry Gill - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

Regis Peffault de Latour - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Paroxysmal nocturnal hemoglobinuria

Eculizumab

OTHER MALIGNANCIES IN THE HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE, MULTICENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY

Thomas Chatzikonstantinou - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

CTX001 FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA: SAFETY AND EFFICACY RESULTS FROM THE ONGOING CLIMB THAL-111 STUDY OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS

Franco Locatelli - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thalassemia

Filgrastim

MULTIPLE MYELOMA DERIVED MITOCHONDRIAL DAMPS PROMOTE A PRO-INFLAMMATORY SIGNATURE WITHIN THE MYELOMA BONE MARROW MICROENVIRONMENT

Aisha Jibril - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

GATA2 HAPLOINSUFFICIENCY REDUCES AGED HEMATOPOIETIC STEM CELL FUNCTIONALITY IN MULTIPLE LINEAGES

Cansu Koyunlar - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

PATIENT PREFERENCES FOR MAINTENANCE THERAPY OF ACUTE MYELOID LEUKEMIA: A DISCRETE CHOICE EXPERIMENT SUBANALYSIS OF PATIENTS IN GERMANY AND ITALY

Katelyn Cutts - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

IDENTIFICATION AND VALIDATION OF A SUBSET OF CANDIDATE FDA-APPROVED DRUGS FOR REPURPOSING IN HOXA EXPRESSING AML

Kate Butcher - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

TRANSCRIPTOMIC CHARACTERISATION OF IGH-TRANSLOCATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA: THE IMPACT OF IGH PARTNER GENES

Kent Fung - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

REAL-WORLD COSTS OF FRONT-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA IN FRANCE, GERMANY, AND THE UNITED KINGDOM

Christopher Fox - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Filgrastim

Filters

45280 Abstracts